The Malaria in Pregnancy (MiP) Consortium, led by the Liverpool School of Tropical Medicine, was established with an initial grant of $30 million from the Bill & Melinda Gates Foundation and is also supported by the European Union and EDCTP. We continue to seek additional funding from other donors.
The six year programme will directly benefit the 50 million women globally who face exposure to malaria whilst pregnant every year.
The primary aims of the research address four key areas:
Obtain a better understanding of the burden of malaria in pregnancy in regions outside Africa where malaria is common but less is known than for Africa.
Further evaluate which of the new generation of antimalarial drugs can be used safely and effectively for the treatment of pregnant women with malaria in Africa, Asia and Latin America.
Identify safe alternative antimalarials for the prevention of malaria in pregnancy in Africa to replace the commonly used drug sulphadoxine-pyrimethamine (to which many malaria parasites have developed resistance).
Public Health Impact
Establish the best way to increase the coverage and utilisation of existing strategies to control malaria in pregnancy.